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Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an
urgent need to identify novel agents for therapy of this disease. Recently, we reported that the oncolytic vaccinia virus GLV-1h68
could be a useful tool for therapy of canine mammary adenoma in vivo. In this study we analyzed the therapeutic eﬀe c to fG L V -
1h68 against canine mammary carcinoma. Cell culture data demonstrated that GLV-1h68 eﬃciently infected and destroyed cells
of the mammary carcinoma cell line MTH52c. Furthermore, after systemic administration, this attenuated vaccinia virus strain
primarily replicated in canine tumor xenografts in nude mice. Finally, infection with GLV-1h68 led to strong inﬂammatory and
oncolytic eﬀects resulting in signiﬁcant growth inhibition of the tumors. In summary, the data showed that the GLV-1h68 virus
strain has promising potential for eﬀective treatment of canine mammary carcinoma.
1.Introduction
Malignant tumors of the mammary glands are among the
most frequently observed tumors in female dogs [1–3].
Despite the success in diagnosis and treatment of mammary
cancer, this disease entity remains one of the leading causes
of cancer-related death in female dogs. Therefore, there is
an urgent need to identify novel agents for therapy and
diagnosis of mammary cancer. Among the most promising
new therapeutic candidates are oncolytic viruses, which can
target tumor tissue and speciﬁcally eradicate the cancer
cells. This concept was already conﬁrmed in human tumor
xenograft treatment by the use of several viruses [4–9].
In the present study, we tested the recombinant oncolytic
vacciniavirusGLV-1h68asatherapeuticagentagainstcanine
mammary carcinoma. The GLV-1h68 virus strain was engi-
neered by inserting expression cassettes encoding a Renilla
luciferase-green ﬂuorescent protein (GFP) fusion protein, β-
galactosidase, and β-glucuronidase into the genome of the
wild-type strain LIVP [10]. In nude mouse models, GLV-
1h68 is highly attenuated compared to the wild-type strain
[10]. We have already demonstrated that the injection of2 Journal of Oncology
GLV-1h68 leads to regression and elimination of diﬀerent
t u m o rx e n o g r a f t si nn u d em i c e[ 10–15]. More recently, we
reported that GLV-1h68 could be a useful tool for therapy of
canine mammary adenoma [12].
Here we describe that the GLV-1h68 virus successfully
infected, replicated, and lysed canine mammary carcinoma
MTH52c cells in cell culture. In addition, GLV-1h68 can
eﬃciently prevent cancer growth in female nude mice with
tumors derived from MTH52c cells. Finally, the localization
and eﬀects of GLV-1h68 in the primary tumor were analyzed
by immunohistochemical studies and by mouse Immune-
Related Protein Antigen Proﬁling.
2.MaterialsandMethods
2.1. Cell Culture. African green monkey kidney ﬁbroblasts
(CV-1) were obtained from the American Type Culture
Collection (ATCC). MTH52c is derived from a malignant
small-cell canine carcinoma [16].
Cells were cultured in DMEM supplemented with antibi-
otic solution (100U/ml penicillin G, 100units/ml strepto-
mycin)and10%fetalbovineserum(FBS;InvitrogenGmbH,
Karlsruhe, Germany) for CV-1 and 20% FBS for MTH52c at
37
◦C under 5% CO2.
2.2. Virus Strain. GLV-1h68 is a genetically stable oncolytic
virus strain designed to locate, enter, colonize, and destroy
cancer cells without harming healthy tissues or organs [10].
2.3. Cell Viability Assay with GLV-1h68. MTH52c cells were
seeded in 24-well plates (Nunc, Wiesbaden, Germany). After
24 hours in culture, cells were infected with GLV-1h68 using
multiplicities of infection (MOI) of 0.1 and 1.0. Cells were
incubated at 37
◦C for 1 hour, after which the infection
mediumwasremoved,andcellsweresubsequentlyincubated
in fresh growth medium. The amount of viable cells
after infection with GLV-1h68 was measured as described
previously [12].
2.4. Viral Replication. For the viral replication assay,
MTH52c cells grown in 24-well plates were infected with
GLV-1h68 at an MOI of 0.1. After one hour of incubation
at 37
◦C with gentle agitation every 20 minutes, the infection
m e d i u mw a sr e m o v e da n dr e p l a c e db yaf r e s hg r o w t h
medium. After 1, 6, 12, 24, 48, 72, and 96 hours, the cells and
supernatants were harvested. Following three freeze-thaw
cycles, serial dilutions of the lysates were titered by standard
plaque assays on CV-1 cells. All samples were measured in
triplicate.
2.5. Western Blot Analysis of Virus-Mediated Marker Proteins.
Three days prior to infection, MTH52c cells were seeded
in 24-well plates (Nunc, Wiesbaden, Germany). If not
otherwise indicated, the 90% conﬂuent cell layer was mock-
infected or infected with GLV-1h68 at MOIs of 0.1 and
1 . 0f o r1h o u ra t3 7
◦C. The virus-containing medium was
aspirated and replaced by fresh medium containing 20%
FBS. For protein isolation and detection, cells were harvested
and resuspended in sodium dodecyl sulfate (SDS) sample
buﬀer at one, 12, 24, 48, 72, and 96 hours post infection
(hpi). The protein samples were separated by 10% SDS
polyacrylamide gel electrophoresis (PAGE) and subsequently
blotted onto a nitrocellulose membrane (Whatman GmbH,
Dassel, Germany). The membrane was then incubated
with anti-beta-actin mouse monoclonal antibodies (ab6276,
Abcam, Cambridge, UK), anti-beta-galactosidase rabbit
polyclonal antibodies (A-11132, Molecular Probes, Leiden,
Netherlands), or anti-GFP rabbit polyclonal antibodies (sc-
8334, Santa Cruz, Heidelberg, Germany), and detection
wasobtainedusinghorseradishperoxidise-labeledsecondary
antibodies against mice (ab6728, Abcam, Cambridge, UK)
or rabbits (ab6721, Abcam, Cambridge, UK) followed by
enhanced chemiluminescence.
2.6. Fluorescence Imaging. The GFP signals of virus-infected
cells and animals were analyzed with a ﬂuorescence micro-
scope (Leica DM IRB; Wetzlar, Germany) and a ﬂuorescence
stereomicroscope (Leica MZ 16 FA; Wetzlar, Germany),
respectively. Images were captured with an electronic camera
and were processed using META-MORPH (Universal Imag-
ing; Downingtown, PA, USA) and Photoshop 7.0 (Adobe
Systems, Mountain View, CA, USA).
2.7. Flow Cytometry (FACS) Analysis. MTH52c cells were
grown on 24-well plates (Nunc, Wiesbaden, Germany) and
i n f e c t e db yG L V - 1 h 6 8a ta nM O Io f0 . 1o r1 . 0 ,r e s p e c t i v e l y .
At various time points, infected and noninfected MTH52c
cells were harvested by Trypsin-EDTA treatment (PAA
Laboratories GmbH, Pasching, Austria) and resuspended in
PBS. For discrimination between viable and dead, MTH52c
cells were stained using 2μl propidium iodide (1mg/ml;
Sigma, Taufkirchen, Germany) per 1 ml cell suspension for
5 min at room temperature. A minimum of 2×105 cells were
then measured using an Epics XL ﬂow cytometer (Beckman
Coulter GmbH Krefeld, Germany).
2.8. Bioluminescence Imaging. For monitoring studies of the
distribution of the GLV-1h68 virus in tumor-bearing mice,
animals were analyzed for the presence of virus-dependent
luciferase activity. For this purpose, mice were injected
intravenouslywithamixtureof5μlofcoelenterazine(Sigma,
Taufkirchen, Germany; 0.5μg/μl diluted ethanol solution)
and 95μl of luciferase assay buﬀer (0.5M NaCl; 1mM
EDTA; 0.1M potassium phosphate, pH 7.4). The animals
were then anaesthetized with 2.5% Isoﬂurane (Forene,
Abbott, Ludwigshafen, Germany) in a knockout box and
were maintained in an anaesthesia module aerated with
1.5% Isoﬂurane/oxygen. The mice were imaged using the
CCD-Camera-based NightOWL LB 981 Imaging System
(Berthold Technologies, Bad Wildbad, Germany). Photons
werecollectedfor5minutesfromdorsalviewsoftheanimals,
and the images were recorded using Image WinLight 32
software (Berthold Technologies, Bad Wildbad, Germany).
2.9. GLV-1h68-Mediated Therapy of MTH52c Xenografts.
Tumors were generated by 5 × 106 implanting cells in 100μlJournal of Oncology 3
PBS subcutaneously into the right hind leg of 6- to 8-week-
old female nude mice (NCI/Hsd/Athymic Nude-Foxn1nu,
Harlan Winkelmann GmbH, Borchen, Germany). Tumor
growth was monitored 3 times weekly in two dimensions
using a digital caliper. Tumor volume was calculated as
[(length × width
2)/2]. On day 12, a single dose of GLV-1h68
virus (5 × 106 plaque forming units [pfu] in 100μl PBS) was
injected into the tail vein (i.v.). The control animals were
injected i.v. with PBS only.
The signiﬁcance of the results was calculated by two-way
analysis of variance (ANOVA) using the GraphPad Prism
software (San Diego, USA). Results are displayed as means ±
s.d. (standard deviation). P-values of <.05 were considered
signiﬁcant.
The animals were euthanized by cervical dislocation.
All animal experiments were approved by the government
of Unterfranken and conducted according to the German
animal protection guidelines.
2.10. Toxicity Studies. Mice with MTH52c xenograft tumors
were developed to assess the biodistribution and toxicity
of the GLV-1h68 virus. After virus infection, animals were
observed daily for any sign of toxicity, and body weight
was checked twice weekly. At day 21 and 42 after injec-
tion, viral distribution in animals from each group was
analyzed. The tumors and organs were excised, inspected,
and homogenized using FastPrep FP120 Cell Disruptor (BIO
101, Qbiogene, Germany) at a speed of 6 for 20s (three
times). After three freeze-thaw cycles, the supernatants were
collectedbycentrifugationat1000×gfor5minutes.Theviral
titers were then determined in duplicate by standard plaque
assays using CV-1 cells.
2.11.HistologicalAnalysisofTumors. Forhistologicalstudies,
tumors were excised and snap-frozen in liquid N2, followed
by ﬁxation in 4% paraformaldehyde/PBS at pH 7.4 for 16
ha t4 ◦C. Tissue sectioning was performed as described by
Weibel et al. [17]. GLV-1h68 was labeled using polyclonal
rabbit antivaccinia virus (anti-VACV) antibody (Abcam,
Cambridge, UK), which was stained using Cy3-conjugated
donkey antirabbit secondary antibodies obtained from Jack-
son ImmunoResearch (West Grove, PA, USA). Phalloidin-
TRITC (Sigma, Taufkirchen, Germany) was used to label
actin.
The ﬂuorescent-labeled preparations were examined
using the Leica MZ 16 FA Stereo-Fluorescence microscope
equipped with a Leica DC500 Digital Camera. Digital images
were processed with Photoshop 7.0 (Adobe Systems, Moun-
tain View, CA, USA) and merged to yield pseudocolored
images.
2.12. Preparation of Tumor Lysates for Mouse Immune-
Related Protein Antigen Proﬁling. GLV-1h68-infected and
noninfected tumors of MTH52c or ZMTH3 xenografted
nude mice were used for preparation of tumor lysates at
42 days after virus infection. Tumors were resuspended in
9v o l u m e s( W / V )l y s i sb u ﬀer [50mM Tris-HCl (pH 7.4),
2mM EDTA (pH 7.4), 2mM PMSF and Complete Mini
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Figure 1:Cytotoxicity(a)andreplication(b)oftheGLV-1h68virus
in canine mammary MTH52c cells. (a) Viability of MTH52c cells
after GLV-1h68 infection using MOIs of 0.1 and 1 was monitored
over 96 hours. The amount of viable cells after infection with GLV-
1h68 was measured in triplicate. Values are shown as percentages of
respective uninfected controls. (b) Viral titer analysis in MTH52c
cell culture after infection with GLV-1h68 at an MOI of 0.1. Cells
and supernatant of virally treated cells were collected at various
times post infection. Viral titers were determined as pfu per well
in triplicate by plaque assay in CV-1 cell monolayers. Average plus
standard deviations plotted.
proteaseinhibitors(Roche,Mannheim,Germany)]andlysed
using a FastPrep FP120 Cell Disruptor (BIO 101, Qbiogene,
Germany) at a speed of 6.0 for 20 s (three times). Samples
were centrifuged at 20,000g at 4◦C for 5 minutes, and
supernatants were then analyzed for mouse immune-related
protein antigen proﬁling by Multianalyte Proﬁles (mouse
MAPs; Rules-Based Medicine, Austin, USA) using antibody-
linked beads. Results were normalized based on total protein
concentration.4 Journal of Oncology
Table 1: Viral titer in tissue samples (pfu/organ or tumor).
Animal no./dpi 1/21dpi 2/21dpi 3/21dpi 4/42dpi 5/42dpi
Liver 120 1716 840 n.d n.d
Lungs 1520 480 n.d. 56 324
Kidneys n.d. n.d. n.d. NT NT
Spleen 150 n.d n.d n.d n.d
Ovaries n.d. n.d 30 NT NT
Tumor 2 ×107 1 ×107 2.1 ×107 7.3 ×105 7.3 ×105
Tumor-bearing mice were injected with 5×106 pfu of GLV-1h68. Mice were sacriﬁced at day 21 or 42 after virus injection (dpi). The data were determined by
standard plaque assays on CV-1 cells using aliquots of the homogenized organs and were displayed as mean pfu/organ or tissue. For each organ, two aliquots
of 0.1ml were measured in triplicates.
n.d.: not detected (detection LIMIT<10pfu/organ).
NT: not tested.
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Figure 2: Western blot analysis of virus-mediated expression of
Renilla luciferase-GFP fusionprotein and β-galactosidase. MTH52c
cells infected with GLV-1h68 at MOIs of 0.1 (a) and 1.0 (b)
were used for protein isolation at 1, 12, 24, 48, 72, and 96 hours
post infection (hpi). The time-dependent expression of Renilla
luciferase-GFP fusion protein (Ruc-GFP), β-galactosidase (LacZ),
and beta-actin as a control was analyzed as described in Materials
and Methods.
3. Results
3.1. Infection and Replication of GLV-1h68 in the Canine
Mammary Cell Line MTH52c. In order to test the ability
of the GLV-1h68 virus to infect and lyse MTH52c cells
in cell culture, we ﬁrst performed a cell viability assay, as
described in Materials and Methods. Ninety-six hours after
GLV-1h68 infection at an MOI of 0.1 and 1.0, the MTH52c
cells were eradicated, with only 2.4 ± 1.04% and 206 ±
0.68%surviving the treatment, respectively (Figure 1(a)).
These results indicate that GLV-1h68 virus infection leads
to an eﬃcient eradication of the carcinoma MTH52c cells in
culture.
To determine the replication eﬃcacy of GLV-1h68 in
MTH52c cells, we analyzed both the supernatant and the
cell-associated virus titers at diﬀerent times post infection
(Figure 1(b)). Whereas the cell-associated virus titer in
MTH52c peaked at 48 hours p.i. (3.94 × 106 pfu/well), the
maximum yield in the supernatant was observed at 96 hours
p.i. (1.54×106 pfu/well).Thesedatacorrelatedverywellwith
cell death and demonstrated that GLV-1h68 can eﬃciently
replicate in MTH52c cells.
In addition, the infectivity of GLV-1h68 was assessed
and compared by virus titration in two pairs of cell lines
(see in Supplementary Material available online at doi
10.1155/2010/736907). In both cases, GLV-1h68 formed
plaques 70–200 times more eﬃciently in cancer cells than
in normal cells, indicating that GLV-1h68 preferentially
replicates in tumor cells.
3.2. Conﬁrmation of Infection and Replication of GLV-1h68
i nM T H 5 2 cC e l l si nC e l lC u l t u r ea n dI nV i v ot h r o u g h
Virus-Mediated Protein Expression. To verify the infection
and replication of GLV-1h68 in canine carcinoma cells,
we followed the expression of the virus-mediated Renilla
luciferase—green ﬂuorescent protein—fusion protein (Ruc-
GFP) and β-galactosidase (LacZ) in cell culture (Figure 2).
Our Western blot analysis revealed that both marker pro-
teins were eﬃciently expressed over a period of four days
(Figure 2). The expression of Ruc-GFP and LacZ in cells
infected at MOI of 0.1 peaked between 48 and 96 hpi,
whereas maximum expression with an MOI of 1.0 was
around 48 hpi.
Similar data were obtained by ﬂuorescence microscopy
(Figure 3). In these experimental settings we found that
MTH52c cells infected with GLV-1h68 at MOI of 0.1 and
1.0 exhibited the strongest GFP expression at 72 and 96
hours, respectively, (supplementary Figure 1 and Figure 3).
T h e s ed a t aw e r ea l s oc o n ﬁ r m e db yﬂ o wc yt o m e t ry( Figure 4)
showingthattheamountofinfectedcellsincreasedovertime
and that those cells infected with vaccinia virus (detectable
by GFP expression) were those cells that exhibited the
major population of dead/dying cells (detectable by positive
propidium iodide staining). In ﬂuorescence microscopy,
we used the same dye to demonstrate that most of the
infected cells were dead/dying at 96h p.i. (Figure 3). These
results indicate that GLV-1h68 was able to eﬃciently infect,
replicate, and kill the MTH52c cells in cell culture.
Next, we examined the eﬃcacy of GLV-1h68 to target
MTH52c tumors in vivo. For this purpose, at diﬀerent days
postinjection, the mice of each group were observed either
under a ﬂuorescence stereomicroscope (Leica MZ 16 FA;
Wetzlar, Germany) to detect GFP-dependent ﬂuorescence or
using the low-light Imager (NightOWL LB 981, Berthold
Technologies, Bad Wildbad, Germany) to detect luciferase-
catalyzed light emission in the presence of intravenously
injected coelenterazine (Sigma, Taufkirchen, Germany). The
GFP and luciferase expressions are dependent on vacciniaJournal of Oncology 5
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Figure 3: Time-dependent eﬀects of infection of MTH52c with GLV-1h68 at an MOI of 1.0. (BF) Transmitted light view of virus-infected
MTH52c cells; (GFP) expression of GFP in infected cells detected by direct ﬂuorescence; (PI) propidium iodide staining of dead cells;
(Merged) colocalization of GFP with the dead cells is shown in the merged imaged. All pictures in this set were taken at the same
magniﬁcation. Scale bars represent 0.1mm.
virus replication in vivo. As demonstrated, GFP ﬂuorescence
and luminescence were detected only within tumors of GLV-
1h68-injected mice (Figure 5). The imaging data indicated
the preferential accumulation of GLV-1h68 in MTH52c
tumors.
3.3. A Single Systemic Application of GLV-1h68 Causes Sig-
niﬁcant Inhibition of Tumor Growth in MTH52c Xenografts.
The therapeutic capacity of GLV-1h68 against an induced
canine mammary cancer was tested in 10 female nude mice
implantedwithMTH52ccellsattheageof6–8 weeks.Twelve
days postimplantation, all nude mice developed tumors with
sizes between 400 and 500mm3.T h e ng r o u p so fﬁ v et u m o r -
bearing mice were injected with either 5 × 106 pfu of GLV-
1h68 or PBS (control). The tumor size of all animals was
measured thrice weekly for six weeks. The single vaccinia
virusinjectioncausedaneﬃcientinhibitionoftumorgrowth
in all GLV-1h68-treated tumor-bearing mice compared to
control mice (Figure 6(a)). In addition, no reduction of net
body weight of the animals was observed (Figure 6(b)).
The data revealed that GLV-1h68 could be an eﬀective
tool for the therapy of canine mammary carcinoma.
3.4. Viral Localization in GLV-1h68-Treated Mice after Inhi-
bition of Tumor Growth. We analyzed the viral distribution
inGLV-1h68-treatedtumor-bearingmicebystandardplaque
assay and immunohistochemical staining. The plaque assay
analysis revealed that viral titers in tumors were 104 to 107
and 103 to 105 times higher than the titers found in all
the other organs combined at day 21 and 42, respectively
(Table 1). These results show that GLV-1h68 can speciﬁcally
infect and replicate in canine cancer cells.
To further examine the tumor tissues, we analyzed the
tissue sections of the primary tumors at 42 days after
virus injection by immunohistology. Microscopic analysis of
viral distribution demonstrated that GLV-1h68 was present6 Journal of Oncology
Table 2: Comparison of mouse immune-related protein antigen proﬁling in primary ZMTH3 and MTH52c tumors with or without GLV-
1h68 at day 42 after virus infection (n = 2). Folds of enhancement (a) or suppression (b) of mouse protein expression after virus injection
are shown.
(a) Protein expression level: upregulated (day 42 after virus infection).
Antigen GLV-1h68/untreated ratio
(MTH52c)
GLV-1h68/untreated ratio
(ZMTH3) Classiﬁcation
Apo A1 7.56 1.21 Anti-inﬂammatory protein
IFN-gamma 4.00 1.8 Proinﬂammatory cytokine
IL-6 7.04 5.52 Proinﬂammatory cytokine
IL-11 6.59 1.6 Pleiotropic cytokine
IL-18 8.00 3.21 Proinﬂammatory cytokine
IP-10 (CXCL10) 29.47 11.21 Interferon-gamma-induced
protein
MCP-1 (CCL2) 18.36 4,99 Proinﬂammatory cytokine
MCP-3 (CCL7) 13.26 2.36 Proinﬂammatory cytokine
MCP-5 (CCL12) 3.84 7.13 Proinﬂammatory cytokine
M-CSF (KC/GROα) 8.28 3.51 Proinﬂammatory cytokine
MDC (CCL22) 4.02 1.97 chemokine
MIP-1beta 9.34 1.66 Proinﬂammatory cytokine
MIP-2 (CXCL2) 6.91 11.93 Proinﬂammatory chemokine
MMP-9 12.68 26.31 Matrix Metalloproteinase-9
TIMP-1 5.05 2.91 Tissue inhibitor of
metalloproteinase type-1
TNF-alpha 6.47 1.5 Proinﬂammatory cytokine
(b) Protein expression level: downregulated (day 42 after virus infection).
Antigen untreated/GLV-1h68ratio
(MTH52c)
untreated/GLV-1h68ratio
(ZMTH3) Classiﬁcation
VWF 1.33 1.01 von Willebrand factor
MIP-1gamma (CCL9) 2.71 1.96 Macrophage inﬂammatory protein
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Figure 4: FACS analysis of MTH52c after infection with GLV-1h68
at MOIs of 0.1 and 1.0. Flow cytometry data indicate percentage of
GFP and propidium iodide (PI) positive or negative cells.
throughout the tumor tissue of virus-infected mice but not
in control mice (Figure 7). As expected, both the virus and
the GFP distribution were similar in the whole tumor tissue,
indicating that in this case GFP expression is an optimal
tool for the monitoring of the GLV-1h68 infection in vivo
(Figure 7AB). In addition, the histological data revealed that
vacciniavirusinfectionledtooncolysisanddamageoftumor
tissue (Figure 7AI).
3.5. Analysis of Host Immune Response in GLV-1h68-Infected
and Noninfected Primary Tumors. In order to analyze the
eﬀects of virus infection in vivo, we determined the mouse
antigen proﬁling of GLV-1h68-infected and noninfected
tumors of MTH52c or ZMTH3 xenografted nude mice.
Canine mammary ZMTH3 adenoma tumors are susceptible
to GLV-1h68 treatment in vivo [12] and therefore were used
as an additional control.
At 42 days after virus injection, MTH52c and ZMTH3
tumors of nude mice with or without GLV-1h68 treatment
wereremovedandusedforgenerationoftumortissuelysates
as described in Material and Methods.Journal of Oncology 7
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Figure 5: Fluorescence and luminescence imaging of MTH52c tumor-bearing mice after virus treatment. Fluorescence (GFP and Merged)
imaging from the local tumor site and luminescence imaging of one representative mouse were taken 11 and 21 days post injection. Min:
minimum; max: maximum.
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Figure 6: Eﬀect of GLV-1h68 on MTH52c tumor growth in nude mice. (a) MTH52c tumor development in mice after GLV-1h68-treatment
versus PBS treatment. Two-way analysis of variance (ANOVA) was used to compare the two corresponding data points of the two groups.
P<. 05 was considered as statistically signiﬁcant ∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001. (b) Body weights of MTH52c cell xenografted mice after
virus treatment.
The data in both xenograft models revealed that GLV-
1h68 injection led to increased production of most of the
tested proinﬂammatory cytokines and chemokines, such as
MCP-1, MCP-3, MCP-5, M-CSF, IP-10, and IL-18 whereas
only the cytokine MIP-1-gamma (CCL9) and the von
Willebrand factor were downregulated (Table 2).
4. Discussion
Despite advances in surgery, radiation, and chemotherapy,
the available treatment options for mammary carcinoma
in dogs are limited and the prognosis for patients with
advanced-stage disease is very poor. Therefore, the develop-
ment of novel agents for therapy and diagnosis of canine
mammary carcinoma is essential.
In this study, we showed for the ﬁrst time that the
recombinant vaccinia virus GLV-1h68 was able to eﬀectively
infect,replicatein,andlysecaninecarcinomacellsinculture.
The viral replication correlated well with cell lysis and
with expression of the marker GLV-1h68 genes encoding β-
galactosidaseand Renilla luciferase-green ﬂuorescent protein
(GFP) fusion protein, respectively. In addition, ﬂow cytom-
etry data (Figure 4) conﬁrmed that the virus-infected cells,
detectable by GFP expression, were those cells that exhibited
the major population of dead/dying cells (detectable by
positive propidium iodide staining).8 Journal of Oncology
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Figure 7: Immunohistochemical staining of MTH52c tumors. Tumor-bearing mice were i.v. injected either with 5 × 106 pfu of At day
42 after injection, GLV-1h68 (A and AI) or PBS (B and BI). whole tumor cross-sections (100μm) were labeled either with antivaccinia
virus or Phalloidin-TRITC (I) antibodies (both red) and analyzed by ﬂuorescence microscopy to detect GFP (green) and actin or vaccinia
virus-dependent (red) ﬂuorescence. Scale bars represent 5mm. ∗Large areas lacking actin staining indicate dead tumor tissue damaged by
GLV-1h68.
Taken together, we did not ﬁnd any evidence of possible
resistance of canine carcinoma cancer MTH52c cells to
infection with vaccinia virus in cell culture.
The current study also demonstrated the ability of GLV-
1h68 to provide highly eﬀective therapy in vivo.W eo b s e rv e d
a signiﬁcant inhibition of tumor growth and damage of
tumor tissue in the GLV-1h68-treated tumor-bearing mice
compared to control mice. Most importantly, the treated
animals appeared in good health without signs of toxicity,
and no reduction of net body weight of virus-infected
mice was observed (Figure 6(b)). In addition, experiments
analyzing viral biodistribution in diﬀerent organs (Table 1),
as well as GFP ﬂuorescence and luminescence studies on the
living mice (Figure 5), conﬁrmed the fact that the GLV-1h68
virus has an outstanding infection and replication capability
and speciﬁcity in tumors [10, 13].
In order to analyze the possible mechanism of tumor
elimination by GLV-1h68 in our MTH52c tumor xenograft
model, we investigated the mouse immune-related protein
antigen proﬁling in the primary tumors with or without
virus injection. In these experimental settings we also used
GLV-1h68-infected tumors of ZMTH3 xenografted nude
mice as an additional control. The data revealed that in
both the MTH52c and the ZMTH3 virus-infected tumors,
the protein expression levels of most of the tested pro-
inﬂammatory cytokines and chemokines were signiﬁcantly
upregulated compared to the corresponding noninfected
tumors (Table 2).
Many of the upregulated proteins, such as MCP-1, MCP-
3, MCP-5, M-CSF, IP-10, and IL-18, augment innate immu-
nity mediated by dendritic cells, neutrophils, macrophages,
and NK cells. Interestingly, similar mouse immune-related
protein antigen proﬁlings were also determinated in other
xenograft models after a single GLV-1h68 injection [13,
18]. Therefore, GLV-1h68 may induce upregulation of the
innate immune system, leading to increasing levels of pro-
inﬂammatory cytokines. This notion is also supported
by recent immunohistological studies demonstrating spe-
ciﬁc peri- and intratumoral inﬁltration of MHC class II-
expressing host cells (like e.g., macrophages, and dendritic
cells) surrounding virus-infected cancer cells [18, 19]. The
presence of activated macrophages or dendritic cells in virus-
infected xenografts only could serve as an evidence for the
association between xenograft eradication and activation
of the innate immune system. These ﬁndings suggest that
activation of the innate immune system may act together
with viral oncolysis to induce inhibition of tumor growth
and tumor eradication in this model. However, which
components ofthe innate immune systemareinvolved in the
elimination of tumor cells remains unknown.
Wehavereported previouslythattheGLV-1h68viruscan
be successfully used for the treatment of canine mammaryJournal of Oncology 9
ZMTH3 adenoma in vivo [12]. The comparison of the
antitumor eﬀects of GLV-1h68 with that of the present study
showed that, in the adenoma xenograft ZMTH3 model,
GLV-1h68 injection led to a faster and more eﬃcient tumor
inhibition and regression than in mice bearing MTH52c
carcinoma tumors. One possible explanation could be the
better replication eﬃcacy of GLV-1h68 in the ZMTH3
tumors compared to that of MTH52c tumors in vivo [12].
However, a signiﬁcant inhibition of the tumor growth was
found in both ZMTH3 and MTH52c xenografts at day 30
after virus injection.
Therefore, GLV-1h68 could be a useful tool for treatment
of both mammary cancer types in canine patients.
5. Conclusion
Our study demonstrates that the attenuated vaccinia virus
strain GLV-1h68 can eﬃciently infect and destroy the canine
mammary carcinoma MTH52c cells in cell culture and
in vivo. In addition, a single systemic administration of
GLV-1h68 causes a signiﬁcant inhibition of tumor growth
in MTH52c xenografts and damage of tumor tissue with-
out detectable eﬀects on the health status of the treated
animals.
In summary, these data indicate that GLV-1h68 is
a promising candidate virus in the treatment of breast
carcinomas in canine patients.
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